Subscribe To

Price Alert Latest News Economic Calendar News

NAMS / NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET. Read More

Demo Live Account See Partner Details

Content Topics

Newamsterdam

Pharma

Present

2023

Cantor

Fitzgerald

Global

Healthcare

Conference

Stock

NAMS

Posted: Sep 20 2023, 08:00

Author Name: GlobeNewsWire

NAMS News

By Seeking Alpha
October 2, 2023

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

New clinical data shows the potential of obicetrapib in treating early Alzheimer's disease in patients with the ApoE4 mutation. The Phase IIa trial de

By GlobeNewsWire
September 20, 2023

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or

By Seeking Alpha
August 19, 2023

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating ro

By The Motley Fool
June 7, 2023

Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

NewAmsterdam is a clinical-stage biopharmaceutical company with a lead therapy candidate that lowers cholesterol levels. The company is examining the

By Seeking Alpha
March 13, 2023

NewAmsterdam: An Underfollowed Dutch Biotech Cardiovascular Biotech

NewAmsterdam Pharma is a Dutch SMID cap biotech focusing on cardiovascular diseases. NewAmsterdam Pharma has a promising pipeline drug called Obicetra

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.